MAML1 and hepatocellular carcinoma: Moreover, Kaplan‒Meier analysis revealed that HCC patients with high MAML1 expression experienced shorter overall survival (Fig. 1D, hazard ratio (HR) = 1.5, p = 0.022), progression-free interval (Supplementary Fig. 1C, HR = 1.67, p < 0.001) and disease-specific survival (Supplementary Fig. 1D, HR = 1.54, p = 0.057), suggesting that MAML1 is a biomarker of a poor prognosis in HCC development.